echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Blood test breakthrough in 2022 could boost Alzheimer's and Parkinson's diagnosis

    Blood test breakthrough in 2022 could boost Alzheimer's and Parkinson's diagnosis

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationTom Lee

    While biomedicine has made progress in cancer and other diseases over the past few decades, neuroscience has proven to be an elusive puzzle


    Oxford Parkinson's screening has an identification rate of 89%

    Oxford Parkinson's screening has an identification rate of 89%

    This month, researchers at the Oxford Parkinson's Disease Centre demonstrated the rationale for a potential new disease test.


    The test, based on previous alpha-synuclein studies, has been shown to correctly and reproducibly identify 89% of Parkinson's patients, while also ruling out 96% of non-Parkinsonian patients


    A drop of blood screening for Alzheimer's disease

    A drop of blood screening for Alzheimer's disease

    C2N Diagnostics, a company developing a blood test for Alzheimer's disease, began rolling out a new test in late 2020


    Although the test itself cannot diagnose Alzheimer's disease, this non-invasive diagnostic method can be used for broader clinical evaluation


    Measuring certain types of tau in blood samples may be a better indicator of disease progression than amyloid beta, says Quanterix, another test development company whose technology has been used in Biogen and Eli Lilly's clinical trials


    Although the test is currently for research use only, Quanterix's blood test received breakthrough designation from the FDA in October, and the company will continue to develop its potential as an aid in the clinical diagnosis of Alzheimer's disease, including for those over the age of 50.


    Reference source: 2022 forecast: Blood test breakthroughs set to move the needle in Alzheimer's, Parkinson's research

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.